The year in charts

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

ten23 health presents its fairstainability impact report

The report discusses ten23’s continued progress, with multiple international certifications and SBTi target validation, demonstrating its commitment to ambitious climate targets.
April 2, 2025

Pharvaris: EU orphan designation granted for treatment of bradykinin-mediated angioedema

April 1, 2025

SOPHiA GENETICS: 2 million patient cases analyzed, setting new milestone for data-driven medicine

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analyzed on the AI-powered analytics Platform SOPHiA DDM. This achievement solidifies SOPHiA GENETICS as the gold-standard provider of actionable insights for patient care, applying AI capabilities shaped by an unmatch
March 18, 2025

Celonic leverages micro-bioreactor platform for perfusion-based bioprocessing

Celonic Group leverages Merck’s Breez micro-bioreactor technology to optimize bioprocessing efficiency and scalability. This technology integration supports Celonic’s efforts to enhance expertise in monoclonal antibody (mAb) development and manufacturing through advanced Next-Generation Technologies. Celonic’s streamlined production, enabled by Merck’s technology, sets new standards in red
March 12, 2025

Torqur: Interim Phase 2 clinical trial results for Actinic keratosis treatment

Full study results are expected in June 2025, but early results demonstrate strong potential; 60% of trial patients experienced full or partial lesion clearance.
March 10, 2025